Bayesian adaptive N-of-1 trials for estimating population and individual
  treatment effects by Senarathne, S. G. Jagath et al.
Bayesian adaptive N-of-1 trials for estimating population and
individual treatment effects
Senarathne SGJ∗ 1, Overstall, AM2, and McGree JM1
1School of Mathematical Sciences, Science and Engineering Faculty, Queensland University of
Technology, Brisbane, Australia
2Southampton Statistical Sciences Research Institute, University of Southampton, Southampton, UK
ABSTRACT
This article proposes a novel adaptive design algorithm that can be used to find optimal treatment
allocations in N-of-1 clinical trials. This new methodology uses two Laplace approximations to
provide a computationally efficient estimate of population and individual random effects within
a repeated measures, adaptive design framework. Given the efficiency of this approach, it is
also adopted for treatment selection to target the collection of data for the precise estimation of
treatment effects. To evaluate this approach, we consider both a simulated and motivating N-of-1
clinical trial from the literature. For each trial, our methods were compared to the multi-armed
bandit approach and a randomised N-of-1 trial design in terms of identifying the best treatment
for each patient and the information gained about the model parameters. The results show that
our new approach selects designs that are highly efficient in achieving each of these objectives.
As such, we propose our Laplace-based algorithm as an efficient approach for designing adaptive
N-of-1 trials.
Keywords: Laplace approximation; Mixed effects model; Multi-armed bandit design; Parameter
estimation; Placebo; Random effect.
1 Introduction
Research in evidence-based medicine is increasingly moving towards informing individualised clini-
cal care. This has led to renewed interest in N-of-1 clinical trials as they provide the strongest level
of evidence for individual decisions (Guyatt et al., 2000). In N-of-1 trials, patients undergo a series
of treatment periods called cycles where each patient receives each treatment (active or placebo)
sequentially in a randomised order. This allows each treatment to be trailed on each patient,
enabling patients to act as their own control. A major benefit of such a design is that individual
and population treatment effects can be estimated through hierarchical modelling approaches as
proposed by Zucker et al. (1997). However, one potential drawback of such a design is that it
remains fixed throughout the entire trial. This is potentially limiting as data collected throughout
the trial are not used to target informative treatment allocations. For this purpose, we propose
a novel adaptive design algorithm for the selection of treatments that target the estimation of
both population and individual treatment effects. Such an approach will therefore provide more
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informative and efficient N-of-1 trials, ensuring the right treatment is selected for the right patient
in personalised care.
N-of-1 trials are typically used to test new and/or competing treatments for chronic diseases that
are relatively stable over time. In typical N-of-1 clinical trials, treatments do not permanently
change the disease or condition, and therefore, once off treatment, the patient will return to
their underlying stable state (after a sufficiently long wash-out period). Such features may seem
restrictive in practice, however, N-of-1 trials have been applied widely to inform clinical care for,
for example, arthritis, asthma, insomnia, attention deficit hyperactivity disorder, hypertension,
sleep disturbance, and fatigue from cancer (Pope et al., 2004; Coxeter et al., 2003; Nikles et al.,
2006; Alemayehu et al., 2017; Nikles et al., 2019; Mitchell et al., 2015). Most notably, N-of-1 trials
will typically recruit far fewer patients than randomised controlled trials making them suitable for
smaller patient cohorts such as those with rare diseases (Stunnenberg et al., 2018; Bellgard et al.,
2019). Further, given individual treatment effects can be estimated, N-of-1 trials are suitable
when there is significant variability in response to treatment as seen, for example, in response to
the treatment of chronic pain (Germini et al., 2017).
To extend the N-of-1 trial design, we consider a Bayesian adaptive design framework as sequential
learning through time fits naturally within this framework, and is a framework where uncertainty
about, for example, the preferred treatment for a given patient is handled most rigorously. A
variety of different adaptive design algorithms have been proposed in the literature (see Ryan
et al. (2016) for a recent review). Such algorithms often use Markov chain Monte Carlo (MCMC)
samplers, importance sampling or sequential Monte Carlo (SMC) methods to update prior infor-
mation at each iteration of the adaptive design process (Palmer and Mu¨ller, 1998; Weir et al., 2007;
McGree et al., 2012, 2016). However, such approaches are not appropriate for designing N-of-1
trials as they are either too computationally expensive and/or do not allow both population and
individual treatment effects to be estimated. As such, new statistical methods are needed that
allow N-of-1 trials to be efficiently and adaptively designed.
For adaptive design of N-of-1 trials, we consider a Laplace approximation to both the log-likelihood
and the posterior distribution of the parameters (Lin and Breslow, 1996; Skaug and Fournier,
2006). As will be shown, this provides an accurate approximation to the posterior distribution of
the population parameters and individual random effects, and can be derived efficiently, without
relying on computationally burdensome Monte Carlo methods. The standard Laplace approxima-
tion to the posterior distribution has been considered previously (Lewi et al., 2009; Long et al.,
2015; Senarathne et al., 2020) but has been limited to independent data settings, and, such as, is
not appropriate for N-of-1 trials. Thus, we propose a new adaptive design and inference algorithm
for N-of-1 trials including an extension to the Laplace approximation for mixed effects models
for use in Bayesian design. To select treatments, we aim to maximise the Kullback-Leibler (KL)
divergence (Kullback and Leibler, 1951) between the prior and the posterior distribution of the
population and individual random effect parameters. Such an approach targets the collection of
data expected to provide the most information about the parameters. To evaluate this approach,
two alternative designs are considered. The first is based on the multi-armed bandit (MAB) de-
sign (Thompson, 1933; Scott, 2010; Villar et al., 2015) where treatments are randomised based
on the probability of being the preferred treatment for a given individual. Of note, our Laplace
approximation allows the MAB design to be employed efficiently at the individual level through
the availability of estimated individual random effects. Secondly, we compare our designs with
those based on a randomised N-of-1 trial design where treatments are randomly selected with
equal probability.
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The outline of the paper is as follows. In Section 2, a motivating N-of-1 trial is introduced, along
with the statistical model used to analyse the data from this trial. Our Bayesian adaptive design
framework is then defined in Section 3. In Section 4, we show how to efficiently approximate
the log-likelihood and the posterior distribution of the parameters. To illustrate our methodolo-
gies, Section 5 focuses on two examples of aggregated N-of-1 trials. The paper concludes with a
discussion of key findings and suggestions for future research.
2 Motivating Example
The majority (60%−90%) of advanced cancer patients experience fatigue, with such fatigue being
related to cancer treatment or the disease itself (Vogelzang et al., 1997; Lawrence et al., 2004).
Cancer-related fatigue (CRF) often persists after the end of treatment and can last for months,
or even years (Bower et al., 2006). As reported in previous studies, CRF is more severe and
persistent than normal fatigue caused by lack of sleep or overexertion, and has a negative impact
on work, social relationships, and daily activities (Curt et al., 2000; Bower, 2014). Despite this,
and the fact that such fatigue has significant detrimental effects on the quality of life of cancer
patients, in most cases it is under-treated as most patients consider fatigue a symptom to be
endured (Vogelzang et al., 1997).
Methylphenidate (MPH), a psychostimulant, is a commonly prescribed medication for the treat-
ment of CRF. However, studies of this medication have yielded conflicting evidence about it’s
effectiveness in treating CRF. Little to no effect was observed by Minton et al. (2011), Kerr et al.
(2012) observed significant improvement in advanced prostate cancer patients. Collectively, the
results of such studies indicated that the effectiveness of MPH on CRF varied depending on the
condition of the patient and cancer type. Such variation motivated the consideration of an N-of-1
clinical trial of MPH by Mitchell et al. (2015). The main goals of the trial were to estimate: (1)
the population treatment effect of MPH on CRF in patients with advanced cancer; (2) individual
treatment effects; and (3) how variable individual treatment effects are within a population of ad-
vanced cancer patients. In this paper, we consider this study as motivation for our methodological
developments to enable adaptive N-of-1 trials to be efficiently designed.
2.1 Data collection and selection
Mitchell et al. (2015) conducted a series of N-of-1 trials on 43 patients over three cycles. In each
cycle, patients were assigned to both MPH (treatment) and placebo in a randomised order. To
ensure patients (and clinicians) were blinded throughout the study, both the treatment and placebo
were administered in capsules that were identical in appearance and taste. To measure CRF, the
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) subscale was used. This is
a survey comprised of 13 questions where each response is measured on a five-point Likert scale.
A total score (which is the primary outcome) is calculated as the sum across all responses, with
higher scores indicating less fatigue.
As reported by Mitchell et al. (2015), 24 patients completed the trial. Among these, 22 pa-
tients completed all six treatment periods (i.e. yielded complete data from three cycles of two
treatments), and these data were considered in this paper to estimate population and individual
treatment effects, and the variability of treatment effects within and between patients.
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2.2 Modelling aggregated N-of-1 trials
The analysis of aggregated N-of-1 clinical trial data can be undertaken within a mixed effects
modelling framework. Such an approach not only allows population effects to be estimated (akin
to that provided by randomised clinical trials) but also allows individual treatment effects to be
estimated. Zucker et al. (2010) provide the foundations for this for N-of-1 clinical trials through
a generalised linear mixed model (GLMM) specified as follows:
g(E[yijk|bi, dijk]) = (β0 + b0i) + (β1 + b1i)dijk, (1)
where E[yijk|bi, dijk] denotes the jth expected observation of the ith patient at the kth cycle, β =
(β0, β1) are the population parameters, bi = (b0i, b1i) are the random effects for the i
th patient, dijk
is the treatment allocation for the jth observation of the ith patient in the kth cycle and g(.) is a link
function which maps between the linear predictor and the space of the expected observation. Here,
dijk can take the value 1 or 0, depending on the treatment allocation (treatment=1, placebo=0).
In this model, random effects b0, b1 are assumed to follow a Normal distribution with zero means
and variances ω0 and ω1, respectively. Further, given the random effects bi, yijk is distributed
according to an exponential family distribution as follows:
f(yijk|bi) = exp
[
yijkζij −B(ζij)
A(φ)
+ C(yijk, φ)
]
where, A, B and C are known functions, φ is the dispersion parameter of the distribution f(·|·),
and ζijs are known as the canonical parameters. When, for example, yijk has a Normal distribution
(conditional on bi and dijk), the variance of yijk is φ = σ
2; the residual variance.
After estimating the parameters in the above model, it can be used to assess population and
individual treatment efficacy. Here, β0 represents the population level average response when re-
ceiving the placebo, and β1 represents the population level difference between the average response
when receiving the treatment compared to placebo. For estimating the individual treatment and
placebo effects, the relevant individual random effect values are added to the population effects.
As such, the average placebo and treatment effects for the ith patient can be expressed as (β0+b0i)
and (β0 + b0i + β1 + b1i), respectively.
3 Adaptive design
Consider an adaptive N-of-1 clinical trial where the goal is to determine with respect to a placebo:
(1) the effectiveness of a given treatment in the population; (2) the effectiveness of a given treat-
ment for each individual; and (3) how variable the effectiveness of treatment is in the patient
cohort. Without loss of generality, we assume that such an adaptive trial can be constructed
by considering treatment selection for each cycle for each patient, iteratively. That is, initially
treatments within the first cycle for the first patient are determined. Then, once data have been
collected from this cycle, treatments for the first cycle for the second patient will be determined,
and so on. Of course, in practice, patients are recruited at different times, thus this ordering may
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not be exactly how a given trial would proceed. However, as will be seen, our proposed methodol-
ogy does not depend on this adaptive structure, and is actually flexible enough to handle the large
variety of design problems that may be encountered in real N-of-1 trials. Within our adaptive
approach, treatments are allocated without constraint. That is, our approach allows allocating
any treatment combination for a given patient within a given cycle. The notion of a cycle is only
retained so that comparisons can be made with standard N-of-1 trials. If we suppose there are
a total of N number of patients in the study and each patient receives one of the N treatments
(including placebo) in each cycle for a total of K cycles.
Then, the design d1:NMK can be expressed as follows:
d1:NMK = (d111, d121, . . . , dijk, . . . , dNMK)
T .
For clarity, consider two treatments (active and placebo) which will be assigned to N = 5 patients
within a single (K = 1) cycle. Given there is only a single cycle, the subscript for K can be
omitted, and we can define the design d1:NM as follows:
d1:NM = (d11, d12, . . . , d15, d21, . . . , d25)
T .
As there are no constraints in our treatment allocations, each of the above design points dij is
either active treatment or placebo. This extends naturally to more than a single cycle, comparing
more than two treatments and enrolling more than five patients into the trial.
Within an adaptive design framework, the Bayesian inference problem is to evaluate the joint
posterior distribution of the population parameters θ = (β, σ2, ω1, ω2) (defined here, for example,
for a Normally distributed response) and the random effects b at each iteration of the adaptive
design. This posterior is typically analytically intractable, therefore we are required to sample
from or approximate the following:
p(θ, b|y1:ijk, d1:ijk) ∝ p(y1:ijk|β, σ2, b, d1:ijk)p(b|ω)p(θ),
where ω = (ω1, ω2) denotes the random effect variances, and p(y1:ijk|β, σ2, b, d1:ijk) denotes
the conditional likelihood of observing data y1:ijk = (y111, . . . , yijk)
T from design d1:ijk given
the population parameters θ and the random effects b, for i = 1, . . . , N , j = 1, . . . ,M and
k = 1, . . . , K. Further, p(b|ω) is the distribution of the random effects b conditional on the
parameters ω, and p(θ) is the prior distribution of the population parameters.
The Bayesian adaptive design problem can then be stated as selecting d(ijk)+1 at each iteration.
Here, depending on the iteration, the design d(ijk)+1 can be either di{j+1}k, d{i+1}jk or dij{k+1}.
That is, in each iteration of this design algorithm, we select a treatment for either the same
patient, the next patient or for the first patient in the study to start the next treatment cycle.
For selecting which treatment to administer, a utility function is defined to reflect the aim of the
study which we assume, based on the three goals stated at the start of Section 3, is parameter
estimation. In general, we denote the utility function as U(d, z,θ, b|d1:ijk, y1:ijk), where z is the
response obtained from running design d. However, as z, θ and b are unknown, the expectation
is taken with respect to the joint distribution of these random variables based on the posterior
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distribution from the previous iteration. This yields the following expected utility:
U(d|d1:ijk, y1:ijk) = Ez,θ,b|d1:ijk,y1:ijk [U(d, z,θ, b|d1:ijk, y1:ijk)]
=
∫
Z
∫
θ
∫
b
U(d, z,θ, b|d1:ijk, y1:ijk)
× p(z|d,β, σ2, b)p(θ, b|d1:ijk, y1:ijk)dbdθdz,
(2)
where the above expected utility U(d|d1:ijk, y1:ijk) is defined based on a continuous response
variable. Extensions to other types of responses are straightforward.
When the utility function does not depend on the population parameters θ and the random effects
b, Equation (2) can be simplified to yield,
U(d|d1:ijk, y1:ijk) =
∫
Z
U(d, z|d1:ijk, y1:ijk)p(z|d)dz, (3)
where p(z|d) is the model evidence.
Thus, at each iteration of the adaptive design process, one seeks to find d∗(ijk)+1 = arg maxd∈D
U(d|d1:ijk, y1:ijk),
and this is termed the optimal design. Unfortunately, the above expression for the expected utility
generally cannot be solved analytically, and thus needs to be approximated. The most common
approach for this is Monte Carlo integration through the simulation of prior predictive data as
follows:
U(d|d1:ijk, y1:ijk) ≈ 1
Q
Q∑
q=1
U(d, zq|d1:ijk, y1:ijk), (4)
where zq ∼ p(z|d).
The adaptive design process described above is outlined in Algorithm 1 where initially the prior
information about the parameters is defined. Typically, in N-of-1 trials, this prior information will
be uninformative or vague but this need not be the case within our framework. Then, throughout
the iterative process, the next optimal design point is found by maximising the expected utility
(line 5), and the next data point is collected (line 6) based on this selected optimal design.
The prior information about the population parameters and the random effects is then updated
based on the information gained from the new data point (line 7). For the examples considered
in this desktop study, data cannot actually be collected. In place of this, we assume data are
generated from an underlying model with specified parameter values. For the motivating study,
this underlying model is based on the results from analysing data from Mitchell et al. (2015).
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Algorithm 1 Bayesian adaptive design algorithm for N-of-1 trials
1: Initialise the prior information p(θ, b) for the population parameters
2: for k = 1 to K do
3: for i = 1 to N do
4: for j = 1 to M do
5: Find the optimal design point d(ijk)+1 by maximising the utility U(d|y1:ijk, d1:ijk)
6: Collect data point y(ijk)+1 at design point d(ijk)+1
7: Update the joint posterior distribution p(θ, b|y1:(ijk)+1, d1:(ijk)+1)
8: end for
9: end for
10: end for
In considering the adaptive design process as outlined in Algorithm 1, there are two main challenges
(at least computationally). The first is efficiently updating prior information as new data arrive
(line 7). Employing methods like MCMC would require re-running this algorithm at each iteration
of the adaptive design. Given the high-dimensional nature of the posterior distribution (i.e. many
random effects to estimate), this will quickly become computationally infeasible. Thus, alternative
approaches are needed. The second difficulty is evaluating the expected utility function which
requires sampling from or approximating a large number of posterior distributions, see Equation
(4). Thus, efficient approaches are needed, and this motivates the development of the new methods
proposed in this paper.
4 Efficient approximation to the joint posterior distribution
A Laplace approximation is used to efficiently approximate the posterior distribution of the pa-
rameters. This approximation is formed by finding the posterior mode and evaluating the inverse
of the negative Hessian matrix of the log posterior density at this mode. These two terms form
the mean and variance-covariance matrix of a multivariate normal distribution approximation to
the posterior distribution. To describe how this Laplace approximation is formed in this paper,
we first show how the posterior mode is located. For this purpose, we first define the likelihood
for random effect models such as those defined in Equation (1). For such models, the likelihood
function is defined by integrating out the random effects as follows:
L(θ; y1:ijk) =
∫
b
p(y1:ijk|θ, b, d1:ijk)p(b|ω)db
=
∫
b
exp{h(b, θ; y1:ijk, d1:ijk)}db,
(5)
where h(b, θ; y1:ijk, d1:ijk) = log p(y1:ijk|θ, b, d1:ijk) + log p(b|ω) is the joint log-likelihood func-
tion for the population parameters and the random effects.
For some models, the above integral can be solved analytically. However, in general, there is no
closed-form solution, so an approach to handle the general case is presented. Accordingly, when
an analytic solution is not available, an approximation is required. Following the work of Breslow
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and Clayton (1993), a Laplace approximation to the log-likelihood function is
lˆ(θ; y1:ijk) = −1
2
log |H(b∗θ)|+ h(b∗θ, θ; y1:ijk, d1:ijk), (6)
where
b∗θ = arg max
b
h(b, θ; y1:ijk, d1:ijk) and (7)
H(b∗θ) =
∂2
{
h(b, θ; y1:ijk, d1:ijk)
}
∂b∂b
′
∣∣∣
b=b∗θ
(8)
is the Hessian matrix evaluated at b∗θ.
Based on the above approximation to the log-likelihood function, the posterior mode of the pop-
ulation parameters can be found as follows:
θ∗ = arg max
θ
lˆ(θ; y1:ijk) + log p(θ). (9)
However, from the above formulation, it can be seen that b∗θ is conditional on θ and θ
∗ is con-
ditional on b∗θ. Hence, to find the posterior mode for both θ and b, conditional optimisation is
used. That is, for an initial value of the population parameters, values of the random effects which
maximise h(b, θ; y1:ijk, d1:ijk) are found. These random effects are then used to approximate the
log-likelihood which is subsequently used to find the posterior mode for θ. This process then
continues until convergence, upon which θ∗ and b∗ denote the mode of the posterior distribution.
It is this mode that is taken as the mean of the multivariate normal approximation to the posterior
distribution.
Once the posterior mode has been found, the Hessian matrix at this point can be evaluated and
used to form the variance-covariance matrix of the multivariate normal distribution. For this, we
note that the model specified in Equation (1) assumes the population parameters are independent
of the random effects, hence this variance-covariance matrix will be block diagonal. The block
corresponding to the random effects can be found via the Hessian matrix in Equation (8), and the
block corresponding to the population parameters can be found as follows:
A(θ∗) =
∂2{lˆ(θ; y1:ijk) + log p(θ)}
∂θ∂θ
′
∣∣∣
θ=θ∗
. (10)
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Algorithm 2 Laplace approximation for the posterior distribution of population and individual
parameters
1: Find θ∗ by maximising Equation (9)
a: For each proposed θ, find b∗θ = arg max
b
h(b, θ; y1:ijk, d1:ijk) and the Hessian matrix H(b
∗
θ)
(Equations (7) and (8))
b: Update approximation to log-likelihood lˆ(θ; y1:ijk), see Equation (6)
2: Given θ∗, find b∗θ∗ and the Hessian matrix H(b
∗
θ∗)
3: Approximate p(θ, b|y1:ijk, d1:ijk) ∼ MVN
(
(θ∗, b∗θ∗),Ω
)
where Ω =
[−A(θ∗)−1 0
0 −H(b∗θ∗)−1
]
The process for approximating the posterior distribution of the population parameters and the
random effects is outlined in Algorithm 2. To initialise the algorithm, a value for the population
parameters is randomly drawn from the prior distribution. Given these values θ, the mode of the
random effects and the Hessian matrix at this mode are found (line 1a). These two quantities are
used to form a Laplace approximation to the log-likelihood function given in Equation (6). Next,
this approximate log-likelihood function is used to approximate a density that is proportional to
the log-posterior distribution of the population parameters. This density is then used to locate the
posterior mode θ∗ of the population parameters. Given θ∗, the mode of the random effects and
the Hessian matrix at this mode are found (line 2). Finally, the (joint) posterior distribution of the
population and individual parameters is approximated using a multivariate normal distribution
(line 3). It is worth noting that when the likelihood function has an analytic solution, computation
of θ∗ is more straightforward as locating the posterior mode of the population parameters can be
undertaken directly without continually updating the approximation to the log-likelihood.
5 Simulation studies
Here, two aggregated N-of-1 trials are considered to demonstrate the adaptive design approach
proposed in Section 3 with the approximations given in Section 4. Since the main objective of
these trials is to determine the preferred treatment at the population and individual patient level,
the KL divergence utility (Kullback and Leibler, 1951) was implemented for treatment selection.
KL divergence is a measure of how different one probability distribution is from another. Lindley
(1956) proposed that such a measure should be used in design selection if one is interested in
maximising the information gain on model parameters. Thus, we implemented this utility as
maximising information will lead to minimising uncertainty about parameter values including
estimates of random effects for each patient. This should therefore reduce the uncertainty about
which treatment is preferred for each patient. The KL divergence utility is
U(d, z|y1:ijk, d1:ijk) =
∫
θ
∫
b
p(θ, b|y1:ijk, d1:ijk, z, d) log
(
p(θ, b|y1:ijk, d1:ijk, z, d)
p(θ, b|y1:ijk, d1:ijk)
)
dbdθ, (11)
where p(θ, b|y1:ijk, d1:ijk) and p(θ, b|y1:ijk, d1:ijk, z, d) denote the prior and the posterior distri-
bution of the population parameters and the random effects, respectively.
When both prior p(θ, b|y1:ijk, d1:ijk) and the posterior distribution p(θ, b|y1:ijk, d1:ijk, z, d) fol-
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low a multivariate Normal distributions with mean vectors (µ0, µ1) and covariance matrices
(Σ0, Σ1), respectively, then the KLD utility can be approximated as follows:
Uˆ(d, z|y1:ijk, d1:ijk) = 1
2
(
tr
(
Σ−10 Σ1
)
+ (µ1 − µ0)TΣ−10 (µ1 − µ0)− η + log
(detΣ0
detΣ1
))
, (12)
where η is the dimension of the two multivariate Normal distributions.
Throughout the examples, one active treatment will be compared to placebo, and hence M = 2.
Given this, treatment will be coded as an indicator variable with ‘1’ denoting active treatment
and ‘0’ denoting placebo. For selecting the optimal design, as there are only two possibilities for
design selection, the expected utility for each will be evaluated, and the choice which yields the
expected utility value is selected. For comparison, we benchmarked this optimal design approach
against the MAB design and a randomised N-of-1 trial design.
A MAB design refers to a sequential experiment in which the goal is to determine the choice
or ‘arm’ that yields the largest ‘reward’. In the context of a clinical trial, each arm represents
a particular treatment (active or placebo), and reward refers to benefit from treatment. The
MAB design determines treatment choice by randomising treatment selection based on probabil-
ities which reflect current knowledge about the preferred treatment allocation for each patient
in the N-of-1 trial. The adaptive design approach proposed in this paper provides a framework
to select MAB designs based on individual specific probabilities, and this offers more flexibility
than previous approaches based on population parameters only (Scott, 2010). Here, benefit from
treatment is based on the posterior predictive distribution for each patient. For example, if a
higher response indicates a higher level of disease severity, then reward can be quantified via the
following probability:
pi(d) = p
(
µid = min(µ
i
0, µ
i
1)
)
, for d ∈ {0, 1}, (13)
where µid = E[yi|d] denotes the posterior mean for treatment d. Within a Bayesian framework,
the reward probability given in Equation (13) can be expressed as an expectation of an indicator
function. Let Id(θ, bi) = 1 if µid(θ, bi) = min(µi0(θ, bi), µi1(θ, bi)), and Id(θ, bi) = 0 otherwise.
Then,
pi(d) =
∫
θ
∫
bi
Id(θ, bi)p(θ, bi|y1:ijk, d1:ijk)dbidθ.
Here, the reward probability pi(d) is evaluated based on the posterior distribution of the population
parameters and the random effects of the ith patient, obtained from the data y1:ijk collected from
all the patients given the treatments d1:ijk up to cycle k.
This reward probability can be approximated by drawing a large number of samples from the joint
posterior distribution of the population parameters and the random effects of the ith patient, and
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evaluating the following:
pˆi(d) ≈ 1
Q
Q∑
q=1
Id(θq, biq), (14)
where (θq, biq) ∼ p(θ, bi|y1:ijk, d1:ijk).
For the randomised N-of-1 design, the entire treatment sequence for each patient for all treatment
cycles (Eg: {1, 0, 0, 1, 0, 1}) can be obtained before starting the experiment. This treatment
sequence is generated in such a way that the patient receives both treatment and placebo within
each treatment cycle in a random order. As such, even though we use an adaptive design approach,
randomised N-of-1 designs do not use the information collected throughout the trial to inform
treatment selection. This is exactly how typical N-of-1 trials are run.
In each of the two examples considered in this paper, a simulation study was undertaken where
experiments were sequentially simulated within our design framework. That is, in each cycle, the
next data point for the ith patient was generated based on the selected optimal design and the
assumed model (Equation (1)) with true parameter values (line 6 in Algorithm 1). Once the data
have been generated, they will be used to update the prior information of the population and
individual parameters. Designs for each patient within a given cycle will be found sequentially
such that M data points will be collected for a given patient, then M data points will be collected
for the next patient. Once all patients have completed the current cycle, a new cycle for the
initial patient will begin. This will continue until all patients complete three cycles. For both
examples, the prior distribution for the parameters was assumed to be vague, and follow Normal
distributions as given in Table 1. These prior distributions were selected as they are relatively
uninformative on the scale of each parameter, and might typically be implemented in practice for
inference.
Table 1: Prior distributions of the population parameters
Parameter Prior distribution
β0 N
(
0, 1002
)
β1 N
(
0, 1002
)
log(σ) N
(
2.5, 1.62
)
log(
√
ω0) N
(
2.5, 1.62
)
log(
√
ω1) N
(
2.5, 1.62
)
As the results are subject to variability through the simulated data, all simulated studies were
repeated 20 times to explore the range of outcomes that could be observed. After the designs were
obtained and the corresponding data for each example was generated, the posterior distributions
were re-evaluated using a standard MCMC approach. This re-evaluation step was undertaken
to remove any potential bias from the Laplace approximation to the posterior distribution. We
note, however, that the posterior distributions from MCMC and the Laplace approximation were
very similar, see Figure S10 in the online supplementary material showing a comparison of these
posterior distributions for the simulated example. In addition, in the supplementary material,
we have provided results from these simulation studies where an alternative distribution (i.e. the
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Poisson distribution) is considered for the response, see Section B. All simulations were carried
out using R 3.5.2, and R code to reproduce the results in this paper is available via the following
GitHub repository, https://github.com/SenarathneSGJ/Adaptive N-of-1 trials design.
5.1 Simulated example
In this example, we investigate the effect of an active treatment over placebo by running an
adaptive N-of-1 trial with 20 patients. Here, the response variable is assumed to follow a Normal
distribution with higher response values indicating a higher level of disease severity (e.g. pain as
measured on a VAS scale). For each patient, six observations were collected over three treatment
cycles, and the above defined three approaches for treatment selection were considered.
Within this simulation study, four design scenarios were considered, each differing in terms of the
parameter values assumed in the underlying generative model. Firstly, we considered a group of
patients in which the between-subject variability was much smaller than the within-subject vari-
ability of the outcome, and where there was a significant difference between treatment and placebo
at the population level. This scenario was considered as a baseline setting, where the remaining
scenarios were defined by changing a parameter value in this baseline. Specifically, in Scenario 2,
we increased the between-subject variability such that it equalled the within-subject variability
of the outcome. Scenarios 3 and 4 were constructed by changing the population treatment effect
such that there was a large and no difference (respectively) between treatment and placebo at
the population level. These four scenarios are summarised in Table 2 by defining the parameter
values used in each.
Table 2: The population parameter values for each design scenario
Parameter Scenario 1 Scenario 2 Scenario 3 Scenario 4
β0 25 25 25 25
β1 -1 -1 -3 0
σ2 9 9 9 9
ω0 2.25 9 2.25 2.25
ω1 2.25 9 2.25 2.25
For each design scenario, separate simulation studies were conducted. In each simulation study,
a set of random effects were generated based on the assumed parameter values, and these were
considered as the true effects for each patient in the study, and thus used to generate ‘real’ data
throughout each N-of-1 trial. Furthermore, the same set of values were also used to calculate
the true treatment effect for each patient, and hence to determine the best treatment (active or
placebo) for each patient via the model described in Equation (1).
Results: Figures 1, 2 and 3 summarise the results from Scenario 1. Here, we first assessed the
posterior precision of the population and random effect parameters when data were collected based
on the optimal (KLD), MAB and randomised N-of-1 designs. For this comparison, we evaluated
the log-determinant of the variance-covariance matrix of the joint posterior distribution after each
cycle of the experiment. Figure 1 shows boxplots of the distribution of the log-determinant values
of each intermediate posterior distribution (for each cycle) for all simulations. As can be seen, the
posterior distributions obtained from optimal designs have lower log-determinant values compared
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to those obtained from MAB and randomised N-of-1 designs. This indicates that the posterior
distributions obtained from the optimal design have higher precision compared to those obtained
from either MAB or randomised N-of-1 design. As more data are collected, the MAB design also
performs relatively well for estimation when compared to the randomised N-of-1 design.
Next, we assessed the designs in terms of identifying the best treatment allocation (active or
placebo) for each patient in the study. For this purpose, we first calculated the true treatment
effects based on the true parameter values as explained in Section 2.2. Then, based on the true
treatment effects, the best treatment assignment dbest for each patient was identified. Next, we
evaluated the probability of identifying the best treatment for each patient based on each of the
three designs. For this, we obtained a large number of samples from the joint posterior distri-
bution of the population parameters and the random effects. Then, for each posterior sample,
we calculated the individual mean response based on each treatment allocation. The required
probability for each patient was then estimated via Equation (14) with d = dbest. These proba-
bilities were evaluated for all independent simulations, and the results were averaged to compare
the performance of optimal, MAB and randomised N-of-1 designs.
Figure 2 shows the probability (with 95% credible intervals) of identifying the best treatment
allocation for each patient after each treatment cycle when the optimal, MAB and randomised
N-of-1 designs were considered for Scenario 1. According to Figure 2, the optimal design has
higher probability values (with less uncertainty) compared to the MAB and randomised N-of-1
designs. For patients who preferred placebo over the treatment (negative treatment difference),
the median probability values were close to 0.5 (not 1) for all designs in this scenario. The reason
these probabilities are not closer to one is that, under the true model (and therefore what will
most likely be inferred from the data), it is likely that for a given patient, the active treatment
will be preferred. Hence, stronger evidence is needed to shift individual effects towards placebo
when compared to patients who prefer the active treatment. This is particularly noticeable in
this simulation study as the between subject variability is small compared to the within subject
variability meaning patients who favour placebo are much less likely to occur than those who
favour treatment. This can be seen by comparing these results to those from Scenario 2 where
the between subject variability is large. As can be seen, probabilities for patients with similar
treatment effect differences are generally closer to 1. Of note, this is not a feature of our approach
to treatment selection, but rather a feature of all designs considered here including the randomised
N-of-1 trial design.
Figure 3 compares the proportion of times the best treatment was administered for each patient
in each cycle when the optimal, MAB and randomised N-of-1 designs were considered. Here,
MAB design chose the best treatment for each patient a larger number of times than the other
two design approaches. The optimal design also chose the best treatment for each patient a
reasonable number of times except for the eleventh patient in the study. As the eleventh patient
had the highest true treatment effect difference, the optimal design selected the placebo a large
number of times. It is quite reasonable to observe such a difference as the optimal designs focus on
learning about parameter values while MAB explores with a preference for the preferred treatment
(based on currently available information). For this patient, it was more beneficial (in terms of
learning about parameter values) to administer the placebo more often than not.
Similar to design Scenario 1, we compared the performance of the optimal, MAB and randomised
N-of-1 designs under the remaining three design scenarios. For all of these three scenarios, the
optimal designs were able to precisely estimate the joint posterior distribution of the population
parameters and the random effects when compared to MAB and randomised N-of-1 designs (see
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Figures S1, S2 and S3 in the online supplementary material). As shown in Figures S4 and S6, when
there was large uncertainty about the random effects (Scenario 2) or a small difference between the
two treatments at the population level (Scenario 4), it was difficult to determine the best treatment
assignment for patients where the difference between treatment and placebo was small. However,
when there was a clear difference between the two treatments at the population level (Scenario
3), it was relatively straightforward to determine the best treatment allocation for each patient
in the study (Figure S5). In all these scenarios, the optimal design performed better than MAB
and randomised N-of-1 designs for determining the best treatment assignment for each patient.
Figures S7, S8 and S9 in the online supplementary material compare the proportion of times the
best treatment was given to each patient when treatments were assigned using the optimal, MAB
and randomised N-of-1 designs under design Scenario 2, 3 and 4, respectively. As can be seen, for
all scenarios, MAB design chose the best treatment for each patient more often than the other
two design methods. However, this did not translate into providing more information about which
treatment is better for each patient (as the optimal design performed best for this). Such results
are expected based on how treatments are selected within each approach.
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Figure 1: The boxplot of the distribution of the log-determinant of the posterior variance-
covariance matrix for each design after each treatment cycle over 20 simulations from Scenario 1
in Example 1.
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Figure 2: The probability (with 95% credible intervals) of identifying the best treatment for each
patient after each cycle when treatments were assigned using optimal, MAB and randomised
N-of-1 designs under Scenario 1 in Example 1.
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Figure 3: The proportion of time that their best treatment was received for each patient in
each treatment cycle when treatments were assigned using optimal, MAB and randomised N-of-1
designs over 20 simulations for three cycles under Scenario 1 in Example 1.
5.2 Motivating example
We now return to our motivating example of MPH trial introduced in Section 2. Based on the data
collected from all 22 patients who completed all three cycles in Mitchell et al. (2015), population
16
and individual parameter estimates were found by fitting the model described in Equation (1).
A simulation study was then undertaken with treatment selection based on the optimal, MAB
and randomised N-of-1 designs. This simulation study was run exactly as outlined for Example
1, including the prior distributions used (see Table 1). Here, the response variable was assumed
to follow a log-normal distribution with higher values indicating less fatigue (higher recovery).
Results: For the purpose of comparing the parameter estimation results, log-determinant values
of the posterior variance-covariance matrix of the population parameters and the random effects
were evaluated and plotted. As shown in Figure 4, the joint posterior distribution based on
the optimal designs have smaller log-determinant values compared to those based on MAB and
randomised N-of-1 designs. That is, the optimal design was relatively efficient for parameter
estimation. Again, as more design points were collected, MAB design performed relatively well
for estimation when compared to the randomised N-of-1 design.
In Figure 5, we compare the probability (with 95% credible intervals) of identifying the best
treatment assignment for each patient after each treatment cycle when the optimal, MAB and
randomised N-of-1 designs were considered for data collection. Similar to the first example, these
probabilities were approximated using Equation (14), but with a different indicator function. Here,
the indicator function equals to 1 if the mean response value of the best treatment assignment for a
given patient is higher than that of the remaining treatment assignment, and 0 otherwise. As can
be seen, the optimal design performed relatively well for this experimental goal when compared
to the other two design methods.
The proportion of times the best treatment was selected for each patient in each treatment cycle
is shown in Figure 6. Again, MAB design selected the best treatment for each patient a larger
number of times when compared to the other two design methods.
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Figure 4: The boxplot of the distribution of the log-determinant of the posterior variance-
covariance matrix for each design after each treatment cycle over 20 simulations from Example
2.
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Figure 5: The probability (with 95% credible intervals) of identifying the best treatment for each
patient after each cycle when treatments were assigned using optimal, MAB and randomised
N-of-1 designs from Example 2.
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Figure 6: The proportion of time that their best treatment was received for each patient in
each treatment cycle when treatments were assigned using optimal, MAB and randomised N-of-1
designs over 20 simulations for three cycles from Example 2.
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6 Discussion
In this work, we have developed a Bayesian adaptive design approach to find optimal treatment
allocations for N-of-1 trials. As was seen, the designs derived from our approach can be used
to determine the best treatment assignment for each patient with a fewer number of treatment
cycles and/or provide more certainty about this after three cycles (typical duration of an N-of-1
trial). The empirical evidence presented in this paper demonstrates that the proposed Bayesian
adaptive framework can be used to efficiently estimate both population parameters and the random
effects in realistically sized N-of-1 trials, and benefits of this approach over alternatives were
demonstrated. As such, we propose this method could be adopted in future N-of-1 trials to
determine appropriateness in real-world settings.
In the first example, four design scenarios were considered to investigate the performance of our
adaptive design approach under different parameter settings. It was found that the optimal designs
were preferred for estimating the population parameters and the random effects when compared to
the MAB and randomised N-of-1 designs. Furthermore, in using the optimal designs, we were able
to determine the best treatment assignment for each patient in a fewer number of treatment cycles.
When there was considerable variability in the random effects and a small difference between the
individual treatment effects, it was difficult to determine the best treatment assignment with our
optimal design approach but this was also observed for the other two approaches considered in
this paper. In all four scenarios, MAB designs chose the best treatment for each patient a larger
number of times than the optimal and randomised N-of-1 designs but we note that this did not
translate into more certainty about which treatment was best for each patient.
When we considered the motivating example for this research, benefits were seen in adopting
our optimal design approach compared to the MAB and randomised N-of-1 designs in terms
of estimating model parameters. Of note, this again translated into more certainty about the
preferred treatment for each patient during and at the end of the study. Thus, it seems as
though more information from the N-of-1 study of MPH could have been obtained if Bayesian
adaptive design methods were implemented. This was also seen when an alternative distribution
was considered for the response (see Section B of the supplementary material). Accordingly, we
hope to explore the use of our methods in real N-of-1 trials into the future.
The two Laplace approximations proposed in this paper to form an approximation to the posterior
distribution of the parameter is different to what has previously been proposed in the literature
by, for example, Overstall et al. (2018). In such work, authors have proposed a single Laplace
approximation formed by considering the conditional likelihood i.e. not integrating out the random
effects. Given this, it is of interest to compare the two approaches to determine which appears
to yield a better approximation to the posterior distribution. To investigate this, a separate
simulation study was undertaken where posterior distributions obtained from both approaches
were compared to that obtained from MCMC. For this, the data generating model defined in
Example 1 with five patients was used to simulate 50 data sets, each based on a typical N-of-1
design with 3 cycles. For each simulated data set, MCMC and the two Laplace-based approaches
were used to form an approximation to the posterior distribution of the parameters. The posterior
mean and variance for all parameters were recorded for each simulation, and the distribution of
these is summarised in Table A1. As can be seen, the posterior distributions obtained from
MCMC and the Laplace approach proposed in this paper have similar mean values, while the
approximation from Overstall et al. (2018) are noticeably different, particularly for the random
effect parameters. Both Laplace approximations appear to underestimate the variance of the
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parameters but this is much more apparent when the approach from Overstall et al. (2018) is
used. An example of the posterior distributions obtained under these three approaches is shown
in Figure A1. The discussed advantages of our Laplace methods are highlighted in this plot.
As discussed throughout this paper, standard N-of-1 trials randomise treatment allocations within
cycles. However, such randomisation has no place in a Bayesian decision-theoretic framework.
In essence, a randomised decision cannot result in a higher expected utility than a determinis-
tic decision. Notwithstanding this, it is recognised that there may be unobserved confounding
variables and that randomisation protects against the effects of these (see O’Hagan and Forster
(2004)). Hence it may be desirable to randomly allocate treatments to patients. Within our
implementation, approaches for randomising treatment allocation based on the expected amount
of information to be gained could be implemented (e.g. Atkinson and Biswas (2005); Ventz et al.
(2019)).
Future development of our adaptive design approach could include extensions to other types of
trials. Of note, cross-over, single case experimental designs and step-wedge designs can be viewed
as special cases of the N-of-1 trial design. Thus, our approach could potentially be adopted within
such settings. Further, it would be interesting to explore our methodologies for designing platform
trials where patients can be allocated to different treatments over time (Berry et al., 2015). Such
trials generally consider more treatments when compared to N-of-1s, and the availability of differ-
ent treatments can varying depending on the patient. Our approach to targeting information at
the population and individual patient level could prove useful in, for example, quickly discounting
ineffective treatments. We plan to explore this in future endeavours.
When designing N-of-1 trials, typically there is some information available about treatment effects
from previously collected data. Such prior information can be used to determine an appropriate
model for which to undertaken adaptive design. However, if not sufficient, then uncertainty at
the model level should be incorporated into the selection of treatments. Of note, the identified
Bayesian adaptive design approach can be extended to incorporate model uncertainty by forming a
non-trivial prior on the model space. Further, in cases where it is desirable to (additionally) learn
which model is most appropriate for the data, dual-purpose utility functions could be considered
(Borth, 1975; McGree, 2017). In cases where different data types and multiple primary and
secondary outcomes are considered, extensions to the work of Senarathne et al. (2020) may prove
fruitful in forming a more accurate approximation to the posterior distribution. These are also
areas of research which we hope to explore in the future.
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Appendix
Comparison between our proposed Laplace approach, MCMC and a Laplace approach
based on the conditional likelihood
Figure A1: The posterior distributions obtained from our proposed Laplace approximation,
MCMC, and a Laplace approach based on the conditional likelihood for Example 1 with 5 patients.
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Section A: Design scenarios in Example 1
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Figure S1: The boxplot of the distribution of the log-determinant of the posterior variance-
covariance matrix for each design after each treatment cycle over 20 simulations from Scenario
2 in Example 1.
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Figure S2: The boxplot of the distribution of the log-determinant of the posterior variance-
covariance matrix for each design after each treatment cycle over 20 simulations from Scenario
3 in Example 1.
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Figure S3: The boxplot of the distribution of the log-determinant of the posterior variance-
covariance matrix for each design after each treatment cycle over 20 simulations from Scenario
4 in Example 1.
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Figure S4: The probability (with 95% credible intervals) of identifying the best treatment
for each patient after each cycle when treatments were assigned using optimal, MAB and
randomised N-of-1 designs from Scenario 2 in Example 1.
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Figure S5: The probability (with 95% credible intervals) of identifying the best treatment
for each patient after each cycle when treatments were assigned using optimal, MAB and
randomised N-of-1 designs from Scenario 3 in Example 1.
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Figure S6: The probability (with 95% credible intervals) of identifying the best treatment
for each patient after each cycle when treatments were assigned using optimal, MAB and
randomised N-of-1 designs from Scenario 4 in Example 1.
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Figure S7: The proportion of time that their best treatment was received for each patient in
each cycle when treatments were assigned using optimal, MAB and randomised N-of-1 designs
over 20 simulations for three cycles from Scenario 2 in Example 1.
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Figure S8: The proportion of time that their best treatment was received for each patient in
each cycle when treatments were assigned using optimal, MAB and randomised N-of-1 designs
over 20 simulations for three cycles from Scenario 3 in Example 1.
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Figure S9: The proportion of time that their best treatment was received for each patient in
each cycle when treatments were assigned using optimal, MAB and randomised N-of-1 designs
over 20 simulations for three cycles from Scenario 4 in Example 1.
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Figure S10: The posterior distributions obtained from MCMC and Laplace approximation
when data were collected based on the optimal treatment assignments over three cycles from
Scenario 1 in Example 1.
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Section B: N-of-1 trial where count data are observed
When the response variable follows a Normal distribution, an analytic expression can be ob-
tained for the integration given in Equation (5). Therefore, for such responses, we can omit
the step 1a in Algorithm 2. However, there are many cases where non-Normal responses are
observed in N-of-1 trials, and we consider such a scenario in this example where for our motivat-
ing example we consider modelling the primary outcome as count data. That is, the response
variable was assumed to follow a Poisson distribution with higher values indicating less fatigue
(higher recovery). As previously considered, the designs were selected for identifying the best
treatment for each patient in the N-of-1 trial using the design approach discussed in Section 3.
Similar to the previous examples, the prior distribution for the parameters was assumed to
be vague, and follow Normal distributions as given in Table 1.
Table 1: Prior distributions of the population parameters for motivating example where the
primary outcome follows a Poisson distribution
Parameter Prior distribution
β0 N
(− 1, 302)
β1 N
(− 1, 302)
log(
√
ω0) N
(− 1, 22)
log(
√
ω1) N
(− 1, 22)
Results: For comparing the parameter estimation results, log-determinant values of the
posterior variance-covariance matrix of the population parameters and the random effects after
each treatment cycle were plotted (Figure S11). As can be seen, the joint posterior distribution
based on the optimal designs have smaller log-determinant values compared to those based
on MAB and randomised N-of-1 designs. This is particularly noticeable for cycles 1 and 2
highlighting how quickly one can learn about the parameter values based on a decision theoretic
approach.
Figure S12 compares the probability (with 95% credible intervals) of identifying the best
treatment assignment for each patient after each cycle when the optimal, MAB and randomised
N-of-1 designs were considered for treatment selection. These probabilities were approximated
using Equation (14) with the same indicator function considered in our motivating example.
As can be seen, the optimal design overall yields the most certainty about which treatment is
preferred for each patient. Most notably, this is observed across each cycle, in general.
The proportion of times the best treatment was selected for each patient in each treatment
cycle is shown in Figure S13. Neither the optimal or the MAB design allocate the preferred
treatment to a given patient that often. At least for the optimal design, such selection translate
into reduced uncertainty about the preferred treatment (Figure S12).
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Figure S11: The boxplot of the distribution of the log-determinant of the posterior variance-
covariance matrix for each design after each treatment cycle over 20 simulations using the count
data from Example 2.
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Figure S12: The probability (with 95% credible intervals) of identifying the best treatment
for each patient after each cycle when treatments were assigned using optimal, MAB and
randomised N-of-1 designs using the count data from Example 2.
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Figure S13: The proportion of time that their best treatment was received for each patient
in each treatment cycle when treatments were assigned using optimal, MAB and randomised
N-of-1 designs over 20 simulations for three cycles using the count data from Example 2.
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